Corbyn Investment Management Inc. MD Has $3.01 Million Position in Zimmer Biomet Holdings, Inc. $ZBH

Corbyn Investment Management Inc. MD raised its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 1.8% in the 2nd quarter, Holdings Channel.com reports. The fund owned 33,047 shares of the medical equipment provider’s stock after buying an additional 574 shares during the period. Corbyn Investment Management Inc. MD’s holdings in Zimmer Biomet were worth $3,014,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in Zimmer Biomet by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 23,052,925 shares of the medical equipment provider’s stock worth $2,609,130,000 after buying an additional 166,763 shares in the last quarter. Dodge & Cox increased its position in shares of Zimmer Biomet by 2.3% during the 1st quarter. Dodge & Cox now owns 19,564,454 shares of the medical equipment provider’s stock worth $2,214,305,000 after purchasing an additional 446,018 shares during the last quarter. Ameriprise Financial Inc. raised its stake in shares of Zimmer Biomet by 236.0% during the 1st quarter. Ameriprise Financial Inc. now owns 4,568,287 shares of the medical equipment provider’s stock worth $517,039,000 after purchasing an additional 3,208,596 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Zimmer Biomet by 251.3% in the 1st quarter. JPMorgan Chase & Co. now owns 2,081,381 shares of the medical equipment provider’s stock valued at $235,571,000 after buying an additional 1,488,918 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of Zimmer Biomet by 2.9% in the first quarter. Dimensional Fund Advisors LP now owns 2,058,898 shares of the medical equipment provider’s stock valued at $233,009,000 after buying an additional 58,060 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Analysts Set New Price Targets

Several analysts have issued reports on ZBH shares. Redburn Partners set a $130.00 price target on shares of Zimmer Biomet in a research report on Thursday, September 18th. Rothschild & Co Redburn initiated coverage on shares of Zimmer Biomet in a report on Thursday, September 18th. They issued a “buy” rating and a $130.00 target price on the stock. UBS Group reduced their price target on Zimmer Biomet from $96.00 to $88.00 and set a “sell” rating for the company in a report on Thursday, November 6th. Roth Capital reissued a “buy” rating on shares of Zimmer Biomet in a research report on Thursday, August 7th. Finally, Stifel Nicolaus set a $110.00 price objective on Zimmer Biomet in a research report on Wednesday, November 5th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Zimmer Biomet currently has a consensus rating of “Hold” and an average price target of $109.00.

Zimmer Biomet Trading Down 0.2%

Shares of ZBH stock opened at $88.52 on Wednesday. The company has a quick ratio of 0.96, a current ratio of 1.87 and a debt-to-equity ratio of 0.54. Zimmer Biomet Holdings, Inc. has a twelve month low of $85.33 and a twelve month high of $114.72. The firm has a market capitalization of $17.54 billion, a P/E ratio of 21.54, a P/E/G ratio of 2.29 and a beta of 0.67. The stock’s fifty day simple moving average is $99.46 and its 200 day simple moving average is $97.29.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.88 by $0.02. The business had revenue of $2 billion during the quarter, compared to analyst estimates of $2.01 billion. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.Zimmer Biomet’s revenue for the quarter was up 9.6% compared to the same quarter last year. During the same period last year, the company earned $1.74 EPS. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th were paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend was Tuesday, September 30th. Zimmer Biomet’s dividend payout ratio (DPR) is 23.76%.

Insiders Place Their Bets

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of the firm’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $104.15, for a total value of $156,225.00. Following the transaction, the senior vice president directly owned 6,833 shares of the company’s stock, valued at approximately $711,656.95. This trade represents a 18.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.39% of the company’s stock.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.